国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語(yǔ)Fran?ais
Opinion
Home / Opinion / Opinion Line

Tariff cuts on imported drugs show pricing system needs reforming

China Daily | Updated: 2018-06-12 07:22
Share
Share - WeChat

CHINA EXEMPTED TARIFFS on 28 categories of imported medicines, including some common anti-cancer drugs, on May 1. But the retail prices of these medicines have remained unchanged till now. Beijing News comments:

It is disappointing that the zero-tariff policy that has been implemented for nearly one and a half months has not yet brought any tangible benefits to patients.

After China cut tariffs on imported cars last month, the retail prices of some imported vehicles came down almost simultaneously. So people have enough reasons to ask why the retail prices of imported medicines have not yet changed.

It is because the imported vehicles' prices are mainly decided by the market, but medicine prices are fixed by the government according to relevant laws and regulations.

Also the prices of medicines are not decided by one department, but based on the negotiations of different departments, such as the National Health Commission, the National Development and Reform Commission, the Ministry of Civil Affairs, as well as the government's bargaining with the pharmaceutical companies, or else determined by purchase bidding.

The complicated procedure means it usually takes several months to adjust the prices of medicines.

Also imported medicines are sold by agents or branches of foreign pharmaceutical companies in China according to the price approved by the authorities. So the adjustment of a medicine's retail price entails negotiations among all the relevant parties.

Some multinational pharmaceutical companies have a strong say in pricing, particularly in the fields they dominate, while, in contrast, the vehicle market is more competitive. Therefore, it is unrealistic to expect a swift reduction in the retail price of medicine after the tax adjustment.

China should reform its medicine pricing policies and streamline the pricing mechanism. And in the negotiations with foreign pharmaceutical companies, we can learn from the practice of other countries and make use of policy options such as compulsory licensing and parallel importation.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
微山县| 宿州市| 木兰县| 泰州市| 二连浩特市| 和田市| 德江县| 明光市| 大埔区| 三亚市| 余姚市| 治多县| 巩义市| 介休市| 上林县| 南皮县| 邓州市| 基隆市| 平原县| 塔城市| 宿松县| 弥勒县| 孟津县| 铜川市| 阿拉善盟| 巫溪县| 平泉县| 赤壁市| 永昌县| 本溪市| 松溪县| 年辖:市辖区| 福州市| 平顶山市| 泽普县| 万荣县| 阜阳市| 扶绥县| 若尔盖县| 阿拉善右旗| 京山县|